Charles River Laboratories Intl. Inc vs Mercadolibre Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Mercadolibre Inc trades at $1,889.85 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Charles River Laboratories Intl. Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Mercadolibre Inc for 117 Days on average.
| CRL | MELI | |
|---|---|---|
Market Cap | $14.23B | $94.13B |
Volume | 1,176,885 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $2.36K |
52-Week Low | $149.93 | $1.55K |
Typical Hold Time | 33 Days | 117 Days |
Enterprise Value | $17.06B | $101.77B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
MercadoLibre (MELI) trades at $1,856.66, down 0.86% on the day, with the stock showing strong fundamental growth despite recent earnings volatility. The company maintains robust revenue expansion, reaching $28.89 billion in 2025, while technical indicators show a bullish trend with support at $1,842 and resistance at $1,870. Recent news highlights MercadoLibre's dominant position in Latin American e-commerce and fintech, with new service expansions in Brazil.
MELI presents a compelling growth story with strong analyst support (24 buy ratings, 0 sell) and a consensus price target of $2,170. However, investors face risks from profit margin compression and macroeconomic headwinds in key markets like Argentina, requiring careful monitoring of execution against high valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →